ALİ İLTER

Dr. ALİ İLTER

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MÖMurat ÖZDEDE
Murat ÖZDEDE
SYSerap Yadigar
Serap Yadigar
AGAlper Tuna Guven
Alper Tuna Guven
SASuat Akgür
Suat Akgür
FAFelemez ARSLAN
Felemez ARSLAN
EBElif Arı Bakır
Elif Arı Bakır
Background: Finerenone is associated with a lower, yet clinically relevant, risk of hyperkalemia compared with steroidal mineralocorticoid receptor antagonists in diabetic kidney disease (DKD) trials. However, real-world data on hyperkalemia and its associated factors are lacking. Methodology: FINE-TURK is a national, observational cohort of DKD patients who were initiated on finerenone. Eligible adults were included; demographic, clinical, and laboratory data were evaluated. The primary outcome (PO) was hyperkalemia risk signal (potassium ≥ 5.0 mEq/L), and the secondary outcome (SO) was clinically meaningful hyperkalemia (potassium ≥ 5.5 mEq/L). Multivariate logistic regression (LR) was used to define features associated with both PO and SO. LR, random forest (RF), gradient boosting, and CatBoost classifiers were used to define important features associated with the PO. Results: 699 patients were included. 259 (37.1%) reached the PO, and 51 (7.3%) reached the SO. Baseline potassium and estimated glomerular filtration rate (eGFR) were the most important variables associated with both outcomes and were consistently identified as the top features across all models. Thiazide use, presence of diabetic retinopathy, and diabetes duration were also associated with the PO. LR demonstrated the highest recall; random forest achieved the highest precision in performance. Discussion: Real-world data suggest that the risk of clinically meaningful hyperkalemia is similar to that in the clinical trials. In parallel with the safety analysis of clinical trials, baseline potassium and eGFR were consistently the most important factors associated with hyperkalemia risk.

25 September 2025 in Nefrología (English Edition)
Verified
Journal Article
Open access
AİALİ İLTER
ALİ İLTER
MOMeric Oruc
Meric Oruc
SKSukran Sarikaya Kayipmaz
Sukran Sarikaya Kayipmaz
EPErgun Parmaksiz
Ergun Parmaksiz
Glomerulonephritis associated with celiac disease (CD) is rarely reported. Here we report a rare case of nephrotic syndrome associated with C3 glomerulopathy (C3G) in a patient with CD. A 19-year-old female with bilateral leg swelling and hypoalbuminemia was referred with an initial diagnosis of nephrotic syndrome. She had also abdominal pain and diarrhea. First a duodenal biopsy confirmed the diagnosis as CD. Nephrotic range proteinuria was detected so then a percutaneous renal biopsy was performed. Renal biopsy revealed membranoproliferative glomerulonephritis (MPGN) with C3 staining. Introduction of a gluten-free diet, ramipril, steroid and mycophenolic acid ameliorated clinical and laboratory parameters at three years follow up. Edema and hypoalbuminemia are common sharing clinical and laboratory parameters presented in not only patients with CD but also with glomerulonephritis. Urine analysis is very important in patients with CD to detect proteinuria. It is important to keep the possible link between CD and glomerulonephritis in mind for clinicians when working up a patient with diarrhea and nephrotic syndrome.

18 September 2019 in Endoskopi Gastrointestinal
Verified
Journal Article
Closed access
AİALİ İLTER
ALİ İLTER
GBGöksel Bengi
Göksel Bengi
MSMüjde Soytürk
Müjde Soytürk
Giriş ve Amaç: Pankreas kistlerinin teşhis sıklığı, günümüzde bilgisayarlı tomografi ve manyetik rezonans görüntüleme gibi kesitsel görüntüleme yöntemlerinin yaygın kullanımı nedeni ile giderek artmaktadır. Pankreas kistik lezyonlarının tedavisini yönetmek çoğu zaman klinisyen için zordur. Bu nedenle ayırıcı tanı yapılması için; öykü, klinik, laboratuvar, radyolojik görüntüleme, endoskopik ultrasonografi, endoskopik ultrasonografi eşliğinde ince iğne aspirasyon biyopsisi ile alınan kist sıvı analizi ve sitopatoloji verilerinin değerlendirilmesi önemlidir. Bu çalışmanın amacı; pankreasın neoplastik kistlerinde klinik, laboratuvar, radyolojik, endosonografik ve patolojik incelemelerin tanıya katkısının psödokistlerle karşılaştırılarak araştırılmasıdır. Gereç ve Yöntem: Çalışmaya Temmuz 2009-Ağustos 2017 tarihleri arasında Dokuz Eylül Üniversitesi Tıp Fakültesi Hastanesi İç Hastalıkları Anabilim Dalı Gastroenteroloji Kliniği Endoskopi ünitesinde pankreas kistik lezyonu nedenli endoskopik ultrasonografi eşliğinde ince iğne aspirasyon biyopsisi ile değerlendirildikten sonra cerrahi operasyon geçiren ve patoloji sonucu “neoplastik kist” olan 30 hasta ile akut pankreatit öyküsü olup pankreas kistik lezyon nedenli endoskopik ultrasonografi eşliğinde ince iğne aspirasyon biyopsisi değerlendirilmesi sonrası endoskopik ultrasonografi raporlarında “psödokist” tanısı konulan 46 hasta dahil edilmiştir. Hastaların; demografik verileri, klinik özellikleri, laboratuvar verileri, radyolojik/ endoskopik ultrasonografi görüntü raporları ve patolojik inceleme sonuçları retrospektif olarak değerlendirilmiştir. Bulgular: Pankreas kistik lezyonu nedenli kiste yönelik cerrahi operasyon geçiren 30 hastanın cerrahi patoloji sonuçları; 15 hastanın (%50) intraduktal papiller müsinöz neoplazi, 6 hastanın (%20) kistik adenokarsinom, 4 hastanın (%13.3) solid psödopapiller neoplazm, 3 hastanın (%10) müsinöz kistik neoplazi ve 2 hastanın (%6.7) seröz kistik neoplazi şeklinde idi. Endoskopik ultrasonografi incelemesinde; pankreasın ve kistlerin morfolojik özelliklerine bakıldığında; neoplastik kist grubunda 2 (%6.7) hastada kronik pankreatit bulguları, 6 (%20) hastada ana pankreas kanalında genişleme, 2 (%6.7) hastada yan dal pankreas kanallarında genişleme, 6 (%20) hastada kistin pankreatik kanal ile bağlantılı olduğu, 9 (%30) hastada septasyon, 5 (%16.7) hastada lobulasyon, 5 (%16.7) hastada kalsifikasyon, 4 (%13.3) hastada kist duvarında kalınlaşma mevcuttu. Psödokist grubunda ise 1 (%2.2) hastada septasyon, 1 (%2.2) hastada lobulasyon mevcuttu. Endoskopik ultrasonografi eşliğinde ince iğne aspirasyon biyopsisi ile alınan kist sıvısı analizinde; neoplastik kist grubunda kist analizinde bakılan amilaz ortalama değeri; 28808.8±60961.01 U/L ve karsinoembriyojenik antijen ortalama değeri: 1055.29±1548.14 ng/mL olarak; psödokist grubunun kist analizinde ise amilaz ortalama değeri: 28246.13±29858.56 U/L ve karsinoembriyojenik antijen ortalama değeri: 7.31±10.02 ng/mL olarak saptanmıştır. Endoskopik ultrasonografi; neoplastik kistlerin 13’ünü (%43.3) tanısal olarak doğru tanımlamıştı. Müsinöz kistlerde; endoskopik ultrasonografinin tanısal olarak ayırt ediciliğine endoskopik ultrasonografi eşliğinde ince iğne aspirasyon biyopsisi bulgularından (sitopatoloji, müsin, string sign ve karsinoembriyojenik antijen >192 ng/mL ) herhangi birinin veya hepsinin pozitif olmasını eklediğimizde; tanısal duyarlılık %88.9’a varan oranlara ulaşmaktadır. Sonuç: Pankreasın neoplastik kistlerinin tanısında endoskopik ultrasonografi ve endoskopik ultrasonografi eşliğinde ince iğne aspirasyon biyopsisi en yüksek tanısal duyarlılığa sahip yöntemdir. Buna rağmen %15’e varan oranda neoplastik/benign kist ayrımını yapmada yeterli olmamaktadır. Radyolojik yöntemlerle birlikte kullanımı tanısal doğruluğu arttırmaktadır. Pankreas kisti bulunan diyabetik hastalarda serum kanser antijen 19-9 düzeylerinin bakılması neoplastik kist tanısında yardımcı olabilir.

24 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AGAlper Tuna Guven
Alper Tuna Guven
SYSerap Yadigar
Serap Yadigar
MÖMurat ÖZDEDE
Murat ÖZDEDE
SASuat Akgür
Suat Akgür
FAFelemez ARSLAN
Felemez ARSLAN
EBElif Arı Bakır
Elif Arı Bakır
Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥ 4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline serum potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (CSH) (≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 to 5.5 mEq/L. Of the 166 patients, 35 (21.1%) developed CSH, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued only in 12 (7.3%) patients. Baseline eGFR, baseline urinary albumin, loop diuretic use and 20mg finerenone dose were associated with CSH. In contrast, baseline serum potassium was not associated with CSH. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.

4 June 2025 in Nefrología
Verified
Journal Article
Open access
AİALİ İLTER
ALİ İLTER
MOMeric Oruc
Meric Oruc
SKSukran Sarikaya Kayipmaz
Sukran Sarikaya Kayipmaz
EPErgun Parmaksiz
Ergun Parmaksiz

Verified
Journal Article
Open access
PDF file
AGAlper Tuna Guven
Alper Tuna Guven
SYSerap Yadigar
Serap Yadigar
MÖMurat ÖZDEDE
Murat ÖZDEDE
SASuat Akgür
Suat Akgür
FAFelemez ARSLAN
Felemez ARSLAN
EBElif Arı Bakır
Elif Arı Bakır
Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (K ≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: A total of 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 and 5.5 mEq/L. Of the 166 patients, 35 (21.1%) reached the primary outcome, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued in only 12 (7.3%) patients. Lower baseline estimated glomerular filtration rate, baseline urinary albumin, loop diuretic use and 20 mg finerenone dose were associated with the primary outcome. In contrast, baseline potassium was not associated with the primary outcome. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.